Positive pre-clinical results, including an advanced high yielding manufacturing process, support the anticipated submission of an IND in 2024 to begin clinical development with Phase 1 single and ...

Antibody-drug conjugates (ADCs) hold great promise as targeted cancer therapeutics. But their complex structure poses significant development and safety challenges for biopharma. In this GEN webinar, ...

Dosed first solid tumor patients with multiplex TCR-T therapy; paused further enrollment to prioritize heme development; reiterates planned data readout in Q1 2026 Enacted ~30% workforce reduction to ...

The ABPI says that industry and academia must come together to bridge the gap between academic and commercially ready preclinical models.

Silo Pharma, Inc., a biopharmaceutical company focused on developing innovative treatments for mental health and chronic pain, announced in a recent letter to shareholders that it expects to submit an ...